2016•Leukemia & lymphoma/Leukemia and lymphomaRequires access

No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab

Christina Kalpadakis, Gerassimos A. Pangalis, Sotirios Sachanas, D. Rontogianni, Penelope Korkolopoulou, Vassilis Milionis, Theodoros P. Vassilakopoulos, Helen Α. Papadaki, Maria K. Angelopoulou

Open publisher page 6 citations

Abstract

Splenic marginal zone lymphoma (SMZL) is an indolent B-cell lymphoproliferative disorder characterized by blood and bone marrow (BM) involvement associated with splenomegaly, while lymphadenopathy ...

About this research paper

What this paper is about

Why it matters

OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Splenectomy, Medicine, Autoimmune hemolytic anemia, Rituximab, Splenic marginal zone lymphoma, Lymphoma, Hemolytic anemia, Spleen